| Disease | THE EFFICACY AND TOLERANCE OF THE STANDARDIZED HAWTHORN(CRATAEGUS) EXTRACT WS 1442 WERE TESTED IN A MULTICENTER UTILIZATION OBSERVATIONAL STUDY. MONITORED 1011 PATIENTS WITH CARDIAC INSUFFICIENCY STAGE NUHA II, TREATED WITH THIS EXTRACT
(CRATAEGUTT NOVO450, 1 TABLE B.I.D.) OVER A PERIOD OF 24 WKS. DURING AND AT THE END OF THE OBSERVATION PERIOD A SIGNIFICANT IMPROVEMENT IN CLINICAL SYMPTOMS (REDUCED PERFORMANCE IN THE EXERCISE TOLERANCE TEST, FATIGUE, PALPITATION AND EXERCISE
DYSPNEA) WAS OBSERVED. ANKLE EDEMA AND NOCTURIA DISAPPEARED BY 83%, AND BY HALF OF THE PATIENTS RESPECTIVELY MANIFESTING THESE SYMPTOMS BEFORE TREATMENT. THE IMPROVEMENT AND ECONOMIZATION OF CARDIAC PERFORMANCE WERE ADDITIONALLY SHOWN BY A
REDUCTION IN BLOOD PRESSURE, AN INCREASED MAXIMAL EXERCISE TOLERANCE AND A REDUCTION IN THE DIFFERENCE IN THE PRESSURE/HEART RATE PRODUCT(PHRP). THE POSITIVE EFFECTS OF WS1442 WERE FURTHER DEMONSTRATED BY AN IMPROVED EJECTION FRACTION AND AN
INCREASED PRECENTILE SHORTENING FRACTION MEASURED USING M-MODE ECHOCARDIOGRAPHY. THE STABILIZING EFFECT OF THE HAWTHORN EXTRACT ON THE HEART RATE WAS SHOWN BY A SLOWER REST PULSE, AS WELL AS BY AN INCREASE IN THE NUMBER OF DAY AND NIGHT
NORMORHYTHMIC PATIENTS, AS DOCUMENTED BY LONG-TERM ECG. THE REDUCTION IN THE NUMBER OF PATIENTS SHOWING ST DEPRESSIONS, ARRHYTHMIAS AND VENTRICULAR EXTRASYSTOLES AT THE MAXIMUM EXERCISE LEVEL IS REGARDED AS AN INDICATION FOR AN IMPROVED
MYOCARDIAL PERFUSION.
A COMMERCIAL PRODUCT, CRATAEGUTT FORTE, WAS USED. |